08 May 2008 - Medgenics announced that it has appointed Dr. Ehud Shoshani, former CEO of Quintiles, Israel, as its Vice President of Clinical Affairs. Dr. Shoshani will manage the Company's Phase I/II clinical trials with EPODURE, its lead sustained-action protein therapy to treat anaemia, which is scheduled to start mid-2008 pending approval by the Israel Ministry of Health (MoH).
Dr. Shoshani's 13 years' experience in managing clinical trials includes his former position as Chief Executive Officer, Medical Director and Head of Clinical Operations of the Israel division of Quintiles. In addition, he has served as Medical Director at Omrix Biopharmaceutical, a blood products company (NASDAQ:OMRI), and at Gamida Cell, a stem cell therapy company.
Dr. Shoshani was awarded his MD in 1978 from the Technion Medical School in Haifa, Israel, and spent the next 16 years specializing in paediatrics, paediatric oncology and haematology before entering industry.
 |
www.bionity.com/news/e/81871 |
|
 |
|
|
© Chemie.DE Information Service GmbH http://www.bionity.com/news/e/81871 |
Seydelstr. 28 · 10117 Berlin info@chemie.de · Tel: +49 (0)30 20 45 68 - 0 |